There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things.

Research presented at the 2026 AAD Annual Meeting examined patterns of skin cancer prevalence in adults aged 50 years and ...

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal ...

The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...

This evening’s session at the 2026 American Academy of Dermatology Annual Meeting focused on an often-overlooked culprit in dermatology: arthropods. Titled “What’s Bugging You? Arthropods of ...

As part of this partnership, Affidea has implemented Skin Analytics’ DERM, an AI medical device software for the automated analysis of skin lesions. The initial implementation of DERM began in Romania ...

Please provide your email address to receive an email when new articles are posted on . Twelve-month data from a large U.S. registry study confirmed the clinical utility and high negative predicative ...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that ...

The diagnostics advisory committee considered evidence on Deep Ensemble for Recognition of Malignancy (DERM) to assess and triage skin lesions referred to the urgent suspected skin cancer pathway from ...

There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things.

DERM is an artificial intelligence (AI)-based skin lesion analysis technology intended for use in the screening, triage and assessment of suspected skin cancer lesions in people aged 18 or over. DERM ...